C4X Discovery is using its unique proprietary technologies to build a pipeline of high quality small molecule drug candidates addressing valuable markets with high unmet medical need.
Since IPO in October 2014, C4X Discovery has been growing it’s drug discovery pipeline and now has 8 drug discovery programmes targeted in the therapeutics areas of Addiction, Diabetes, Chronic Obstructive Pulmonary Disease, Psoriasis, Oncology (including immuno-oncology) and Rheumatoid Arthritis.
Recently, Taxonomy3® has identified multiple novel targets in discrete patient subgroups for the treatment of Parkinson’s Disease that could potentially provide an opportunity in stratified medicine. The Company has recently reproduced the analysis from a second patient dataset confirming this discovery. The selection process to choose the first target to be prosecuted in a drug discovery programme is now underway with the expectation of initiating at least one programme by the end of the year.
Further genetic dataset analysis is underway in other neurodegenerative and inflammatory disorders with the aim of discovering novel drug targets to expand the pipeline further.
Information on selected drug discovery programmes is below.
(Inititated Nov 15)
Hot GPCR targets lacking target protein crystal structure at project initiation
Marketed Biologics (clinically validated) with small molecule opportunity
Intracellular target protein structure available, novel hit finding less successful with conventional screening but enabled by C4X